TuesdayJul 30, 2024 11:44 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Long-Term Study Results Confirm Positive Results of Developing Treatment for AD

InMed Pharmaceuticals (NASDAQ: INM), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, is reporting on positive results from a long-term study of INM-901. The in vivo preclinical Alzheimer's disease (“AD”) involved seven months of dosing and confirms findings from an earlier short-term pilot study. The company reported that results from the study confirm improvements in cognitive function, memory and locomotor activity and show statistical significance in certain behavioral assessments.According to the announcement, InMed is moving forward with additional molecular analyses to better define the mechanisms of action and…

Continue Reading

WednesdayJul 17, 2024 2:47 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the receipt of interim results from the first four weeks of dosing in its ongoing diabetes animal study WEIGHT-A24-1. The company noted that the results have already produced several noteworthy findings. According to the announcement, unlimited food and water have been provided to the animals for the entire duration of the study. During the initial acclimation phase, which spanned 34 days before the beginning of dosing, the animals gained 10.9% body weight on average. During the subsequent 28 days of DehydraTECH-processed drug therapy dosing, all test…

Continue Reading

TuesdayJul 16, 2024 1:31 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Makes Management Announcement, Plans for Strategic Growth

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is preparing for growth by executing a strategic growth plan. A key element of the plan includes expanding the company’s management team to enable efficient handling of a greater workload of projects and initiatives. With that in mind, the company has named Nelson Cabatuan as consulting chief strategic financial advisor; Cabatuan is currently serving as Lexaria CFO. In his new role, Cabatuan will leverage his skills in corporate finance and strategic industry relationships to focus on strategic opportunities. In addition, Lexaria is working on other research and development projects…

Continue Reading

TuesdayJul 09, 2024 2:27 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes Dosing in Second GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that human pilot study #2, GLP-1-H24-2, has now completed all dosing. The final DehydraTECH study arm used a Rybelsus(R) composition processed with DehydraTECH that is compliant with the FDA’s Inactive Ingredient Database (“FDA IID”), delivered within an in-mouth dissolvable tablet. According to the announcement, this will be the first study designed to investigate whether DehydraTECH-enhanced semaglutide can absorb at any level systemically through the sublingual/buccal tissues of the mouth and throat with fewer side effects than from swallowed administration, and with some effective drug delivery into…

Continue Reading

MondayJul 08, 2024 3:45 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Secures New Patents for Antiviral Drug Delivery, Treating Epilepsy

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced three new patent awards. In the European Union, the company received a new patent in Lexaria’s patent family #6: Transdermal and/or Dermal Delivery of Lipophilic Active Agents. Following an earlier one granted in Canada, this is the company’s second patent in this family. In Canada, Lexaria has received a new patent in patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. This is the company’s fourth granted patent in this family, which was previously granted in the U.S., Australia and Japan. Further, building…

Continue Reading

TuesdayJul 02, 2024 11:02 am

CannabisNewsBreaks – Golden Triangle Ventures Inc. (GTVH) CEO Shares Insight into Dynamic Operations, Visionary Goals Through Spaces Event

Golden Triangle Ventures (OTC: GTVH) (“GTV”) today announced the availability of the replay for its highly anticipated July 1 Spaces event on X.com. The event was hosted by GTV’s CEO, Steffan Dalsgaard, who delivered a complete overview of GTV’s multifaceted business activities, including a key highlight of its flagship Destino Ranch project. During the live session, Dalsgaard provided comprehensive insights into the company’s diverse business, strategic initiatives and ambitious future growth plans. The event garnered significant attention and was met with enthusiasm from shareholders and the general public, offering a rare glimpse into Golden Triangle Ventures’ dynamic operations and visionary…

Continue Reading

TuesdayJun 18, 2024 2:11 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Engages CRO for DehydraTECH GLP-1 Human Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to oversee execution of the company’s 12-week chronic study GLP-1-H24-4. The study will evaluate various DehydraTECH-GLP-1 (glucagon-like peptide) formulations and other treatments with efficacy objectives of weight loss, blood sugar reduction and more. “This study will be the most comprehensive and impactful GLP-1 investigation that Lexaria has ever undertaken,” said John Docherty, president of Lexaria. “The greatly expanded scope compared to our previous studies will allow us to investigate DehydraTECH-GLP-1 safety and efficacy over an extended treatment duration…

Continue Reading

TuesdayJun 11, 2024 1:14 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation at Upcoming Emerging Growth Conference

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, will be featured in this week’s Emerging Growth Conference. The conference is slated for June 12–13, 2024. According to the announcement, InMed Pharmaceuticals CEO Eric A. Adams will be presenting at the two-day event. During his presentation, Adams will provide a corporate overview of the company; the presentation will also include a Q&A session. Adams’ presentation is scheduled to begin at 1:45 p.m. EDT on June 13. An archived replay of the presentation will be available on the InMed Pharmaceuticals website.…

Continue Reading

WednesdayJun 05, 2024 2:51 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting that the second round of dosing for all nine study participants in the second arm of its human pilot study #2 has been completed. The company anticipates completion of the final arm of the study, GLP-1-H24-2, in July. A three-arm, crossover investigation that compares three 7 mg semaglutide dose formulations, the study evaluates three doses: a positive control Rybelsus(R) swallowed tablet; DehydraTECH-semaglutide swallowed capsule; and for the first time ever, an in-mouth dissolvable DehydraTECH-semaglutide oral tablet. The study is designed to measure tolerability and side effects as well…

Continue Reading

WednesdayMay 22, 2024 1:18 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Granted Two New US Patents in Hypertension, Epilepsy

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received two new patent awards, bringing the company’s patent portfolio to 43 granted patents worldwide. According to the announcement, the company has been granted a patent in its patent family #21, “Compositions and Methods for Treating Hypertension.” The company noted that this is the third granted U.S. patent in this category and is regarding the company’s DehydraTECH(TM)-processed cannabidiol (“CBD”) and evidence of its ability to lower blood pressure in both acute dosing in hypertension as well as during a five-week study duration. In addition, Lexaria has received a granted patent…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000